Progenity
Biora Therapeutics Settles Claims of Misleading Genetic Testing Advertisements
The company, formerly known as Progenity, was accused of violating consumer protection laws by making misleading claims about the costs of its genetic testing services.
The firm alleges its competitors infringe its patents describing processes for finding chromosomal abnormalities in fetal cell-free DNA.
Enumera Molecular Acquires Progenity Liquid Biopsy Tech, Raises $12.5M in Series A Round
Progenity will receive an ownership stake in the newly formed venture, which is being headed by its former CSO Matthew Cooper.
Progenity, Natera Jointly Request Dismissal of Patent Litigation
Progenity sought a declaratory judgment from a California court last year that its Innatal NIPT test didn't infringe six patents held by Natera.
Progenity Raises $40M in Private Placement
The firm said it will use the funds to support its operations, to invest in its molecular testing research and development program, and for working capital.
May 13, 2021
Progenity Q1 Revenues up 46 Percent
Feb 23, 2021
Progenity Enters $25M Private Placement
Nov 9, 2020
Progenity Q3 Revenues Increase 38 Percent
Oct 23, 2020
BTIG Initiates Coverage of Progenity With Buy Rating
Jun 16, 2020
Progenity Eyes $122.6M in Amended IPO
May 29, 2020
Progenity Files for IPO, Seeks to Raise up to $100M
Apr 18, 2019